Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front Med    2014, Vol. 8 Issue (1) : 101-105     DOI: 10.1007/s11684-014-0315-5
RESEARCH ARTICLE |
Methodologies for the establishment of an orthotopic transplantation model of ovarian cancer in mice
Cunjian Yi1(), Lei Zhang1, Fayun Zhang2, Li Li1, Shengrong Ling1, Xiaowen Wang1, Xiangqiong Liu1, Wei Liang2()
1. Department of Obstetrics and Gynecology, First Affiliated Hospital of the Yangtze University, Jingzhou 434000, China; 2. Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
Download: PDF(128 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract  

This study used different methods to establish an animal model of orthotopic transplantation for ovarian cancer to provide an accurate simulation of the mechanism by which tumor occurs and develops in the human body. We implanted 4T1 breast cancer cells stably-transfected with luciferase into BALB/c mice by using three types of orthotopic transplantation methodologies: (1) cultured cells were directly injected into the mouse ovary; (2) cell suspension was initially implanted under the skin of the mouse neck; after tumor mass formed, the tumor was removed and ground into cell suspension, which was then injected into the mouse ovary; and (3) a subcutaneous tumor mass was first generated, removed, and cut into small pieces, which were directly implanted into the mouse ovary. After these models were established, in vivo luminescence imaging was performed. Results and data were compared among groups. Orthotopic transplantation model established with subcutaneous tumor piece implantation showed a better simulation of tumor development and invasion in mice. This model also displayed negligible response to artificial factors. This study successfully established an orthotopic transplantation model of ovarian cancer with high rates of tumor formation and metastasis by using subcutaneous tumor pieces. This study also provided a methodological basis for future establishment of an animal model of ovarian cancer in humans.

Keywords ovarian cancer      orthotopic transplantation      animal model     
Corresponding Authors: Yi Cunjian,Email:cunjiany@163.com; Liang Wei,Email:weixx@sun5.ibp.ac.cn   
Issue Date: 26 April 2014
URL:  
http://academic.hep.com.cn/fmd/EN/10.1007/s11684-014-0315-5     OR     http://academic.hep.com.cn/fmd/EN/Y2014/V8/I1/101
Fig.1  luminescence imaging of BALB/c mouse tumor models by transplanting 4T1-LUC cells. (A) Subcutaneous tumor model; (B) Orthotopic transplantation model using cultured cell suspension; (C) Orthotopic transplantation model using cells ground from subcutaneous tumor mass; (D) Orthotopic transplantation model using tumor pieces dissected from subcutaneous tumor mass.
Fig.2  luminescence imaging of orthotopic transplantation model using tumor pieces dissected from subcutaneous tumor mass. (A) 10 d, (B) 20 d, (C) 50 d, and (D) 50 d with opened abdominal cavity.
1 Hoffman RM. Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic. Invest New Drugs 1999; 17(4): 343-360
doi: 10.1023/A:1006326203858 pmid:10759402
2 Manzotti C, Audisio RA, Pratesi G.Importance of orthotopic implantation for human tumors as model systems: relevance to metastasis and invasion. Clin Exp Metastasis 1993; 11(1): 5-14
doi: 10.1007/BF00880061 pmid:8422706
3 Muller W J, Swanson I. Orthotopic and Ectopic Models of Metastasis.Experimental and Clinical Metastasis. Springer New York , 2013: 227-236
4 Ricci F, Broggini M, Damia G. Revisiting ovarian cancer preclinical models: implications for a better management of the disease. Cancer Treat Rev 2013; 39(6): 561-568
doi: 10.1016/j.ctrv.2013.01.005 pmid:23434073
5 Hoffman RM, Yang M. Whole-body imaging with fluorescent proteins. Nat Protoc 2006; 1(3): 1429-1438
doi: 10.1038/nprot.2006.223 pmid:17406431
6 Deng XH, Sato K. Matrigel animals in the establishment of human tumor xenograft model research. Tumor (Zhong Liu) 1996; 16: 89-91 (in Chinese)
7 Yin AL, Zhong M, Sun GQ, Wang LP, Zhao SS. GFP-labeled human ovarian cancer orthotopic transplantation model. J South Med Univ (Nan Fang Yi Ke Da Xue Xue Bao) 2008; 28(3): 484-490 (in Chinese)
8 Li J, Xing H, Gao QL. Human ovarian carcinoma in nude mice model establishment and biological characteristics. Chin J Obstet Gynecol (Zhonghua Fu Chan Ke Za Zhi) 2003; 38: 376-378 (in Chinese)
9 Jenkins DE, Yu SF, Hornig YS, Purchio T, Contag PR. In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 2003; 20(8): 745-756
doi: 10.1023/B:CLIN.0000006817.25962.87 pmid:14713108
10 Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clinical Cancer Research 2003; 9(1): 327-337
pmid:12538485
[1] Xianxian Li, Hui Xing, Lin Li, Yanli Huang, Min Zhou, Qiong Liu, Xiaomin Qin, Min He. Clinical significance of para-aortic lymph node dissection and prognosis in ovarian cancer[J]. Front Med, 2014, 8(1): 96-100.
[2] Zhiyuan Zhang. Bone regeneration by stem cell and tissue engineering in oral and maxillofacial region[J]. Front Med, 2011, 5(4): 401-413.
[3] Sowmya Viswanathan, Armand Keating. Overcoming the challenges of conducting translational research in cell therapy[J]. Front Med, 2011, 5(4): 333-335.
[4] Wen-Qiang CHEN MD, Yun ZHANG MD, PhD, FACC, . Molecular mechanisms and therapeutic strategies of vulnerable atherosclerotic plaques[J]. Front. Med., 2010, 4(1): 36-42.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed